Objective
Unwanted immune responses to self-tissues and transplants have a major impact on human health and wealth. Their management has required long-term immunosuppressive drugs which penalise the whole immune system. The big challenge has been to understand how the individual is naturally tolerant to self, and to exploit this knowledge for treatments better targeted to the relevant antigens. Since 1980 the applicant’s laboratory have, in rodent models, defined mechanisms of acquired tolerance, and used monoclonal antibodies to transiently block lymphocyte function, or deplete lymphocytes with the goal of establishing tolerance therapeutically. This led to the discovery of ”infectious tolerance” where tolerance was shown to require regulatory CD4+FoxP3+ T cells. Although efficacious in rodent models, equivalent blockading antibodies for man, although available, have not been commercialised by the pharmaceutical industry. To deplete lymphocytes in man, our laboratory has also developed the anti-CD52 monoclonal antibody, CAMPATH-1H. This was the first humanised therapeutic antibody (Alemtuzumab/Lemtrada) and is being actively pursued for multiple sclerosis and stem cell and organ transplantation. Although lymphocyte depletion has clearly proven to be clinically useful, it has not, when used alone, permitted tolerance to transplanted organs or allowed for durable immune reprogramming in autoimmune disease. This proposal seeks to understand how to build on the benefits of lymphocyte depletion with CAMPATH-1H, and promote tolerance by exploiting tolerance–promoting mechanisms learned from our studies of co-receptor/co-stimulation blockade. The novel approach taken by this project is to investigate and manipulate the reconstitution phase of lymphocyte recovery through Physician Aided Reconstitution of the Immune System (PARIS), by aiming to contain those T-cells that mediate damage whilst empowering competing regulatory T-cells.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine neurology multiple sclerosis
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences basic medicine immunology autoimmune diseases
- medical and health sciences clinical medicine transplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
ERC-2013-ADG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Host institution
OX1 2JD Oxford
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.